Olfr569 Inhibitors
Olfr569, a member of the G-protein-coupled receptor (GPCR) family, plays a crucial role in recognizing and transducing odorant signals, contributing to the intricate process of olfactory perception. As part of the largest gene family in the genome, Olfr569 contributes to the diversity and specificity of odorant detection. The potential inhibition of Olfr569 involves targeting specific signaling pathways associated with its function. Tetrodotoxin and Nifedipine, as voltage-gated ion channel blockers, modulate olfactory signaling pathways by disrupting ion channel activity and calcium homeostasis, respectively. Pertussis Toxin inhibits Olfr569 through G protein interference, disrupting the normal functioning of the receptor. H-89 and Rolipram affect Olfr569 through the cAMP/PKA pathway, leading to altered expression and function. LY294002 and Wortmannin, as PI3K inhibitors, influence Olfr569 through the PI3K/Akt pathway, interfering with downstream effectors crucial for normal functioning.
Amiloride, a sodium channel blocker, influences Olfr569 by modulating ion homeostasis, and Verapamil, a calcium channel blocker, indirectly disrupts Olfr569 function by affecting calcium homeostasis. TAK-733 and U0126, as MEK inhibitors, affect Olfr569 through the MAPK/ERK pathway, leading to altered expression and function. Thapsigargin, a SERCA inhibitor, disrupts calcium homeostasis, potentially leading to decreased expression and function of Olfr569. In summary, the potential inhibition of Olfr569 involves modulating specific biochemical and cellular pathways associated with olfactory signal transduction. Targeting these pathways with various inhibitors may provide insights into understanding and controlling the function of Olfr569 in the complex process of odorant perception.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $58.00 $170.00 | 15 | |
Voltage-dependent L-type calcium channel blocker influencing Olfr569 indirectly. Nifedipine disrupts calcium homeostasis, modulating olfactory signaling pathways and consequently leading to decreased expression and function of Olfr569. | ||||||
Pertussis Toxin (islet-activating protein) | 70323-44-3 | sc-200837 | 50 µg | $442.00 | 3 | |
ADP-ribosylating agent inhibiting Olfr569 through G protein interference. Pertussis toxin disrupts GPCR-mediated transduction, leading to altered expression and function of Olfr569 as a downstream consequence of G protein inhibition. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
PI3K inhibitor affecting Olfr569 through the PI3K/Akt pathway. LY294002 disrupts the PI3K pathway, modulating Olfr569 activity by interfering with downstream effectors crucial for its normal functioning. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $75.00 $212.00 | 18 | |
Phosphodiesterase (PDE4) inhibitor affecting Olfr569 through cAMP regulation. Rolipram elevates cAMP levels, modulating olfactory signaling pathways and consequently leading to altered expression and function of Olfr569. | ||||||
Amiloride | 2609-46-3 | sc-337527 | 1 g | $290.00 | 7 | |
Sodium channel blocker influencing Olfr569 by modulating ion homeostasis. Amiloride disrupts cellular ionic balance, indirectly suppressing Olfr569 expression and signaling by altering the intracellular environment. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $367.00 | ||
Calcium channel blocker influencing Olfr569 indirectly. Verapamil disrupts calcium homeostasis, modulating olfactory signaling pathways and consequently leading to decreased expression and function of Olfr569. | ||||||
TAK-733 | 1035555-63-5 | sc-364630 sc-364630A | 5 mg 10 mg | $340.00 $640.00 | 1 | |
MEK inhibitor affecting Olfr569 through the MAPK/ERK pathway. TAK-733 disrupts the MAPK/ERK signaling cascade, resulting in altered expression and function of Olfr569 as a downstream consequence of pathway inhibition. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
PI3K inhibitor influencing Olfr569 through the PI3K/Akt pathway. Wortmannin disrupts the PI3K pathway, modulating Olfr569 activity by interfering with downstream effectors crucial for its normal functioning. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
MEK inhibitor affecting Olfr569 through the MAPK/ERK pathway. U0126 disrupts the MAPK/ERK signaling cascade, resulting in altered expression and function of Olfr569 as a downstream consequence of pathway inhibition. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
SERCA inhibitor indirectly inhibiting Olfr569. Thapsigargin disrupts calcium homeostasis, modulating olfactory signaling pathways and consequently leading to decreased expression and function of Olfr569. | ||||||